AstraZeneca to Launch Soliris in Hangzhou After Regulatory Approval
UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) has revealed plans to sell Soliris (eculizumab)...
Akeso Biopharma’s AK112 Receives Two New Breakthrough Therapy Designations
The Center for Drug Evaluation (CDE) website indicates that China-based Akeso Biopharma (HKG: 9926) has...
CStone Launches Patient Assistance Program for IDH1 Inhibitor Tibsovo
CStone Pharmaceuticals (HKG: 2616) has announced the launch of a patient assistance scheme to support...
HutchMed Announces Initial Results from FRUTIGA Phase III Study
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) has announced the initial results from...
BRL Medicine Raises RMB 200M in Series B Financing for CGT Development
BRL Medicine Inc., a cell and gene therapy (CGT) developer based in Shanghai, has reportedly...
Peijia Medical Enrolls First Patient in HighLife TSMVR Study
China’s Peijia Medical Limited (HKG: 9996) has announced the enrollment of the first patient and...
Acotec Scientific Secures FDA 510(k) Approval for Vericor Catheter
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received a 510(k)...
CStone Pharmaceuticals Suspends Operations at Suzhou Plant to Cut Costs
CStone Pharmaceuticals (HKG: 2616) has decided to suspend manufacturing operations at its Suzhou industrialization plant,...
Daxiang Biotech Raises RMB 100M in Pre-Series B Financing for Organoid-on-a-Chip
Beijing-based Daxiang Biotech Co., Ltd., a leading domestic company in the organoid-on-a-chip field, has reportedly...
Harbin Gloria Pharmaceuticals Faces Change in Control Amid Bankruptcy
China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has disclosed that its controlling shareholder, Harbin...
HitGen Partners with Daewoong Pharmaceutical for Drug Discovery
China-based HitGen Inc. (SHA: 688222) has announced a research collaboration agreement with South Korea’s Daewoong...
AstraZeneca and CICC Capital Launch RMB 3 Billion Fund in Hangzhou
The joint venture (JV) between UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) and China’s CICC...
Henlius Biotech’s BRAF V600E Inhibitor HLX208 Approved for Clinical Study in China
China-based Shanghai Henlius Biotech (HKG: 2696) has announced that the National Medical Products Administration (NMPA)...
China Updates Hypertension Guidelines, Lowers Diagnostic Threshold
The National Center for Cardiovascular Diseases, the Chinese Medical Doctor Association (CMDA), and other organizations...
AstraZeneca Reports 19% YOY Revenue Growth in Q3 2022
UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) released its Q3 2022 earnings report, showing...
FDA Approves Phase Ib Study for Jiangsu Yahong’s APL1401 in Ulcerative Colitis
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced that...
Baheal Partners with AstraZeneca for Commercial Rights to Onglyza
China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with AstraZeneca...
EQRx Shifts Strategy Amid FDA Feedback on China-Sourced Data
US-based EQRx Inc. (Nasdaq: EQRX), a biopharma originally established with the aim of “radically” disrupting...
Peking University Study Identifies Liver Cancer Immune Microenvironment Subtypes
Researchers at Peking University have uncovered several subtypes in the tumor immune microenvironment (TIME) relevant...
CDE Prioritizes Review for Jiedi Pharma’s Mitotane and Other Key Drugs
The Center for Drug Evaluation (CDE) website indicates that market filings for several key drugs,...